| 106 |
Astragaloside IV protects against ischemia/reperfusion (I/R)-induced kidney injury based on the Keap1-Nrf2/ARE signaling pathway
|
1
|
2024-07-05 11:58:23 |
| 105 |
Integrative transcriptomics and proteomics analysis reveal the protection of Astragaloside IV against myocardial fibrosis by regulating senescence
|
1
|
2024-07-05 11:54:45 |
| 104 |
Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/ caspase-1/GSDMD signaling pathway
|
1
|
2024-07-05 11:50:52 |
| 103 |
Preventive effects of astragaloside IV and its active sapogenin cycloastragenol on cardiac fibrosis of mice by inhibiting the NLRP3 inflammasome
|
1
|
2024-07-05 11:50:16 |
| 102 |
Astragaloside IV Ameliorates Isoprenaline-Induced Cardiac Fibrosis in Mice via Modulating Gut Microbiota and Fecal Metabolites
|
1
|
2024-07-05 11:48:11 |
| 101 |
Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway
|
1
|
2024-07-05 11:47:24 |
| 100 |
AstragalosideⅣ against cardiac fibrosis by inhibiting TRPM7 channel
|
2
|
2024-07-05 11:46:11 |
| 99 |
Astragaloside IV inhibits isoprenaline induced cardiac fibrosis by targeting the reactive oxygen species/mitogen activated protein kinase signaling axis
|
1
|
2024-07-05 11:45:30 |
| 98 |
Astragaloside IV Alleviates Infarction Induced Cardiomyocyte Injury by Improving Mitochondrial Morphology and Function
|
2
|
2024-07-05 11:43:50 |
| 97 |
Astragaloside IV Ameliorates Myocardial Infarction Induced Apoptosis and Restores Cardiac Function
|
1
|
2024-07-05 11:36:00 |
| 96 |
A Single, Acute Astragaloside IV Therapy Protects Cardiomyocyte Through Attenuating Superoxide Anion-Mediated Accumulation of Autophagosomes in Myocardial Ischemia-Reperfusion Injury
|
1
|
2024-07-05 11:35:09 |
| 95 |
A Preclinical Systematic Review and Meta-Analysis of Astragaloside IV for Myocardial Ischemia/Reperfusion Injury
|
1
|
2024-07-05 11:34:12 |
| 94 |
Tetramethylpyrazine and Astragaloside IV have synergistic effects against spinal cord injury-induced neuropathic pain via the OIP5-AS1/miR-34a/ Sirt1/NF-κB axis
|
1
|
2024-07-05 11:30:55 |
| 93 |
Astragaloside IV ameliorate acute alcohol-induced liver injury in mice via modulating gut microbiota and regulating NLRP3/caspase-1 signaling pathway
|
1
|
2024-07-05 11:23:10 |
| 92 |
Astragaloside IV attenuates lipopolysaccharide induced liver injury by modulating Nrf2-mediated oxidative stress and NLRP3-mediated inflammation
|
1
|
2024-07-05 11:22:20 |
| 91 |
Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR mediated autophagy
|
1
|
2024-07-05 11:14:59 |
| 90 |
Astragaloside IV Attenuates Acetaminophen-Induced Liver Injuries in Mice by Activating the Nrf2 Signaling Pathway
|
1
|
2024-07-05 11:13:34 |
| 89 |
Astragaloside IV inhibits epithelial-mesenchymal transition and pulmonary fibrosis via lncRNA-ATB/miR-200c/ZEB1 signaling pathway
|
1
|
2024-07-05 11:12:13 |
| 88 |
Integrating Network Pharmacology and Experimental Validation to Explore the Pharmacological Mechanism of Astragaloside IV in Treating Bleomycin-Induced Pulmonary Fibrosis
|
1
|
2024-07-05 11:11:02 |
| 87 |
Inhibitory Effects of Astragaloside IV on Bleomycin-Induced Pulmonary Fibrosis in Rats Via Attenuation of Oxidative Stress and Inflammation
|
1
|
2024-07-05 11:08:09 |